Regulus Therapeutics reported $39.67M in Equity Capital and Reserves for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Equity Capital And Reserves Change
Alnylam Pharmaceuticals ALNY:US USD -67638000 243.68M
Astrazeneca AZN:US USD 35.13B 798M
AstraZeneca AZN:LN USD 35.13B 798M
Biogen BIIB:US USD 12.78B 903M
Celldex Therapeutics CLDX:US USD 345.42M 19.68M
Gilead Sciences GILD:US USD 21.06B 821M
GlaxoSmithKline GSK:LN GBP 9.15B 7.22B
Intercept Pharmaceuticals ICPT:US USD 107.68M 477.51M
Intrexon XON:US USD 142.53M 86.88M
Lexicon Pharmaceuticals LXRX:US USD 144.02M 73.19M
Ligand Pharmaceuticals LGND:US USD 816.3M 13.93M
Omeros OMER:US USD -46314000 13.61M
Regulus Therapeutics RGLS:US USD 39.67M 2.7M
Sangamo Biosciences SGMO:US USD 309.15M 9.13M
Spectrum Pharmaceuticals SPPI:US USD 35.85M 2.41M
Takeda 4502:JP JPY 6.71T 396.1B
Vital Therapies VTL:US USD 108.81M 19.04M
YTE INCY:US USD 4.23B 141.59M